Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label first-in-human PET biodistribution study of 89Zr-labeled GSK3128349 in healthy men
NL-OMON42953Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of GSK3128349, sponsored by GSK. Primary endpoint: Biodistribution of 89Zr-GSK3128349. Started Aug 2016; status: active, not recruiting.
02
Drugs
GSK3128349
Beyond the preview
Go deeper on NL-OMON42953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42953.